mebendazole has been researched along with Disease Models, Animal in 35 studies
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These preclinical findings indicate that mebendazole alone or in combination with radiation can be considered for the treatment of malignant meningioma." | 7.88 | Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma. ( Riggins, GJ; Skibinski, CG; Williamson, T, 2018) |
| "Flubendazole offers a great potential to become a drug of choice in the preventive treatment of cystic echinococcosis." | 7.76 | Chemoprophylactic activity of flubendazole in cystic echinococcosis. ( Alvarez, L; Ceballos, L; Confalonieri, A; Denegri, G; Elissondo, C; Lanusse, C; Sánchez Bruni, S, 2010) |
| "Mebendazole was highly effective against the helminth parasite Trichinella spiralis in mice subjected to a 3-day course of treatment during the invasive and encystment phases of experimental trichinellosis." | 7.66 | Mebendazole therapy of parenteral trichinellosis. ( McCracken, RO; Taylor, DD, 1980) |
| "Mebendazole (MBZ) is an efficacious anthelmintic with known anti-inflammatory and fibrinolytic properties." | 5.72 | Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis. ( Ahadi, M; Asgharzadeh, F; Askarnia-Faal, MM; Avan, A; Eskandari, M; Ferns, G; Gharib, M; Hassanian, SM; Khazaei, M; Naghibzadeh, N; Naimi, H; Ryzhikov, M; Soleimani, A; Vossoughinia, H, 2022) |
| "Mebendazole is an antihelminthic drug that exerts its effects via interference with microtubule function in parasites." | 5.40 | Mebendazole reduces vascular smooth muscle cell proliferation and neointimal formation following vascular injury in mice. ( Eitzman, DT; Guo, C; Lawler, A; Luo, W; Reddy, A; Sun, EB; Wang, H; Wang, J, 2014) |
| "Mebendazole has been approved by the US Food and Drug Administration for parasitic infections, has a long track-record of safe human use, and was effective in our animal models with doses documented as safe in humans." | 5.37 | Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. ( Aprhys, CM; Bai, RY; Gallia, GL; Riggins, GJ; Staedtke, V, 2011) |
| "Flubendazole has shown poor in vivo efficacy against CE in humans and mice." | 5.35 | Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice. ( Alvarez, L; Bruni, SS; Ceballos, L; Denegri, G; Elissondo, M; Lanusse, C, 2009) |
| "This study evaluates the effectiveness of gastric acid secretion inhibitors (omeprazole and ranitidine), gastric mucosal protectants (sucralfate) and anthelmintics (mebendazole and flubendazole) in treating anisakiasis in Wistar rats." | 4.02 | Acute Anisakiasis: Pharmacological Evaluation of Various Drugs in an Animal Model. ( Arrebola, F; Gómez-Mateos, M; González, JM; Navarro, MC; Romero, MC; Valero, A, 2021) |
| "These preclinical findings indicate that mebendazole alone or in combination with radiation can be considered for the treatment of malignant meningioma." | 3.88 | Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma. ( Riggins, GJ; Skibinski, CG; Williamson, T, 2018) |
| "Mebendazole (MBZ), first used as an antiparasitic drug, shows preclinical efficacy in models of glioblastoma and medulloblastoma." | 3.81 | Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. ( Bai, RY; Gallia, GL; Joshi, A; Riggins, GJ; Rudek, MA; Staedtke, V; Wanjiku, T, 2015) |
| "Flubendazole offers a great potential to become a drug of choice in the preventive treatment of cystic echinococcosis." | 3.76 | Chemoprophylactic activity of flubendazole in cystic echinococcosis. ( Alvarez, L; Ceballos, L; Confalonieri, A; Denegri, G; Elissondo, C; Lanusse, C; Sánchez Bruni, S, 2010) |
| "Mebendazole was highly effective against the helminth parasite Trichinella spiralis in mice subjected to a 3-day course of treatment during the invasive and encystment phases of experimental trichinellosis." | 3.66 | Mebendazole therapy of parenteral trichinellosis. ( McCracken, RO; Taylor, DD, 1980) |
| "Mebendazole (MBZ) is an efficacious anthelmintic with known anti-inflammatory and fibrinolytic properties." | 1.72 | Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis. ( Ahadi, M; Asgharzadeh, F; Askarnia-Faal, MM; Avan, A; Eskandari, M; Ferns, G; Gharib, M; Hassanian, SM; Khazaei, M; Naghibzadeh, N; Naimi, H; Ryzhikov, M; Soleimani, A; Vossoughinia, H, 2022) |
| " Systemic exposures of FBZ/FBZ metabolites achieved following dosing were measured by pharmacokinetic (PK) bioanalysis." | 1.51 | Short-course, oral flubendazole does not mediate significant efficacy against Onchocerca adult male worms or Brugia microfilariae in murine infection models. ( Akumtoh, DN; Aljayyoussi, G; Baeten, B; Chounna, PWN; Chunda, VC; Engelen, M; Fombad, FF; Gandjui, NVT; Lachaud, S; Metuge, HM; Ndzeshang, BL; Njouendou, AJ; Pionnier, N; Quirynen, L; Sjoberg, HT; Steven, A; Taylor, MJ; Tayong, DB; Tekle, F; Turner, JD; Wanji, S; Ward, SA, 2019) |
| " In summary, oral doses of ASD formulated FBZ did not significantly reduce total worm burden but longer treatments, extended takedown times or a second dosing regimen, may decrease female fecundity and the number of mf shed by female worms." | 1.51 | Efficacy of subcutaneous doses and a new oral amorphous solid dispersion formulation of flubendazole on male jirds (Meriones unguiculatus) infected with the filarial nematode Brugia pahangi. ( Baeten, B; Beerntsen, B; Bulman, CA; Engelen, M; Fischer, C; Gut, J; Ibiricu Urriza, I; Lachau-Durand, S; Lim, KC; Lustigman, S; Quirynen, L; Sakanari, J; Tekle, F, 2019) |
| "Benzimidazole drugs are used for treatment of trichinellosis, but they have a limited effect against encapsulated larval stages of Trichinella spiralis." | 1.46 | Implication of artemisinin nematocidal activity on experimental trichinellosis: In vitro and in vivo studies. ( Abou Rayia, DM; Ashour, DS; Oreiby, RM; Saad, AE, 2017) |
| "12-fold increase in the bioavailability of the drug." | 1.43 | Enhancing the bioavailability of mebendazole by integrating the principles solid dispersion and nanocrystal techniques, for safe and effective management of human echinococcosis. ( Chaudhary, S; Garg, T; Goyal, AK; Murthy, RR; Rath, G, 2016) |
| "Mebendazole is an antihelminthic drug that exerts its effects via interference with microtubule function in parasites." | 1.40 | Mebendazole reduces vascular smooth muscle cell proliferation and neointimal formation following vascular injury in mice. ( Eitzman, DT; Guo, C; Lawler, A; Luo, W; Reddy, A; Sun, EB; Wang, H; Wang, J, 2014) |
| "Mebendazole (MBZ) is an extremely insoluble and therefore poorly absorbed drug and the variable clinical results may correlate with blood concentrations." | 1.40 | Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose. ( Bolás-Fernández, F; de la Torre-Iglesias, PM; García-Rodriguez, JJ; Torrado, G; Torrado, S; Torrado-Santiago, S, 2014) |
| "Flubendazole (FLBZ) is a broad-spectrum benzimidazole anthelmintic compound." | 1.38 | Nematodicidal activity of flubendazole and its reduced metabolite on a murine model of Trichinella spiralis infection. ( Confalonieri, A; Ignacio Alvarez, L; Lanusse, C; Sánchez Bruni, S; Urbizu, L, 2012) |
| "Mebendazole has been approved by the US Food and Drug Administration for parasitic infections, has a long track-record of safe human use, and was effective in our animal models with doses documented as safe in humans." | 1.37 | Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. ( Aprhys, CM; Bai, RY; Gallia, GL; Riggins, GJ; Staedtke, V, 2011) |
| "Flubendazole has shown poor in vivo efficacy against CE in humans and mice." | 1.35 | Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice. ( Alvarez, L; Bruni, SS; Ceballos, L; Denegri, G; Elissondo, M; Lanusse, C, 2009) |
| "), when treated with a dosage of 20 mg/kg for 5 consecutive days (99." | 1.31 | Efficacy of flubendazole and albendazole against Trichinella spiralis in mice. ( Cho, SW; Chung, MS; Joo, KH; Kwon, HS; Quan, FS, 2001) |
| "Mebendazole was given to mice infected with Angiostrongylus costaricensis at a single dose of 5 mg/kg at 6, 11, 16 or 21 days post-infection (p." | 1.29 | Effects of mebendazole on Angiostrongylus costaricensis in mice, with special reference to the timing of treatment. ( Akyol, CV; Kino, H; Sano, M; Terada, M, 1993) |
| "Albendazole was the most effective agent in reducing cyst growth and was, when compared with other regimes significantly more effective than mebendazole (p less than 0." | 1.28 | Comparison of albendazole, mebendazole and praziquantel chemotherapy of Echinococcus multilocularis in a gerbil model. ( Morris, DL; Reffin, D; Richards, KS; Taylor, DH, 1989) |
| "The role of mebendazole in treatment of hydatid disease was investigated in a mouse model of human Echinococcus granulosus infection." | 1.27 | In vivo efficacy of mebendazole in containment of larval cyst mass in early stages of hydatid disease due to Echinococcus granulosus. ( Ganguly, NK; Mahajan, RC; Wangoo, A, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (22.86) | 18.7374 |
| 1990's | 2 (5.71) | 18.2507 |
| 2000's | 5 (14.29) | 29.6817 |
| 2010's | 16 (45.71) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Stetter, N | 1 |
| Hartmann, W | 1 |
| Brunn, ML | 1 |
| Stanelle-Bertram, S | 1 |
| Gabriel, G | 1 |
| Breloer, M | 1 |
| Eskandari, M | 1 |
| Asgharzadeh, F | 1 |
| Askarnia-Faal, MM | 1 |
| Naimi, H | 1 |
| Avan, A | 1 |
| Ahadi, M | 1 |
| Vossoughinia, H | 1 |
| Gharib, M | 1 |
| Soleimani, A | 1 |
| Naghibzadeh, N | 1 |
| Ferns, G | 1 |
| Ryzhikov, M | 1 |
| Khazaei, M | 1 |
| Hassanian, SM | 1 |
| Gómez-Mateos, M | 1 |
| Arrebola, F | 1 |
| Navarro, MC | 1 |
| Romero, MC | 1 |
| González, JM | 1 |
| Valero, A | 1 |
| Skibinski, CG | 1 |
| Williamson, T | 1 |
| Riggins, GJ | 3 |
| Sjoberg, HT | 1 |
| Pionnier, N | 1 |
| Aljayyoussi, G | 1 |
| Metuge, HM | 1 |
| Njouendou, AJ | 1 |
| Chunda, VC | 1 |
| Fombad, FF | 1 |
| Tayong, DB | 1 |
| Gandjui, NVT | 1 |
| Akumtoh, DN | 1 |
| Chounna, PWN | 1 |
| Ndzeshang, BL | 1 |
| Lachaud, S | 1 |
| Tekle, F | 3 |
| Quirynen, L | 3 |
| Engelen, M | 3 |
| Baeten, B | 3 |
| Steven, A | 1 |
| Ward, SA | 1 |
| Taylor, MJ | 1 |
| Wanji, S | 1 |
| Turner, JD | 1 |
| Fischer, C | 1 |
| Ibiricu Urriza, I | 1 |
| Bulman, CA | 1 |
| Lim, KC | 1 |
| Gut, J | 1 |
| Lachau-Durand, S | 2 |
| Beerntsen, B | 1 |
| Lustigman, S | 2 |
| Sakanari, J | 2 |
| Hübner, MP | 1 |
| Ehrens, A | 1 |
| Koschel, M | 1 |
| Dubben, B | 1 |
| Lenz, F | 1 |
| Frohberger, SJ | 1 |
| Specht, S | 1 |
| Mackenzie, CD | 1 |
| Hoerauf, A | 1 |
| Cho-Ngwa, F | 1 |
| Mbah, GE | 1 |
| Ayiseh, RB | 1 |
| Ndi, EM | 1 |
| Monya, E | 1 |
| Tumanjong, IM | 1 |
| Mainsah, EN | 1 |
| Wang, J | 2 |
| Wang, H | 1 |
| Guo, C | 1 |
| Luo, W | 1 |
| Lawler, A | 1 |
| Reddy, A | 1 |
| Sun, EB | 1 |
| Eitzman, DT | 1 |
| de la Torre-Iglesias, PM | 1 |
| García-Rodriguez, JJ | 1 |
| Torrado, G | 1 |
| Torrado, S | 1 |
| Torrado-Santiago, S | 1 |
| Bolás-Fernández, F | 1 |
| Chaudhary, S | 1 |
| Garg, T | 1 |
| Rath, G | 1 |
| Murthy, RR | 1 |
| Goyal, AK | 1 |
| Bai, RY | 2 |
| Staedtke, V | 2 |
| Wanjiku, T | 1 |
| Rudek, MA | 1 |
| Joshi, A | 1 |
| Gallia, GL | 2 |
| Deardorff, K | 1 |
| Ray, W | 1 |
| Winterstein, E | 1 |
| Brown, M | 1 |
| McCornack, J | 1 |
| Cardenas-Garcia, B | 1 |
| Jones, K | 1 |
| McNutt, S | 1 |
| Fulkerson, S | 1 |
| Ferreira, D | 1 |
| Gény, C | 1 |
| Chen, X | 1 |
| Belofsky, G | 1 |
| Dondji, B | 1 |
| Abou Rayia, DM | 1 |
| Saad, AE | 1 |
| Ashour, DS | 1 |
| Oreiby, RM | 1 |
| Ceballos, L | 2 |
| Elissondo, M | 1 |
| Bruni, SS | 1 |
| Denegri, G | 2 |
| Alvarez, L | 2 |
| Lanusse, C | 3 |
| Wabo Pone, J | 1 |
| Mbida, M | 1 |
| Bilong Bilong, CF | 1 |
| Elissondo, C | 1 |
| Sánchez Bruni, S | 2 |
| Confalonieri, A | 2 |
| Xiao, SH | 1 |
| Xue, J | 1 |
| Xu, LL | 1 |
| Zhang, YN | 1 |
| Qiang, HQ | 1 |
| Richardson, DJ | 1 |
| Brink, CD | 1 |
| Aprhys, CM | 1 |
| Urbizu, L | 1 |
| Ignacio Alvarez, L | 1 |
| Ostlind, DA | 1 |
| Mickle, WG | 1 |
| Smith, SK | 1 |
| Cifelli, S | 1 |
| Ewanciw, DV | 1 |
| Elbiaze, M | 1 |
| Kaul, CL | 1 |
| Talwalker, PK | 1 |
| Sen, HG | 1 |
| Grewal, RS | 1 |
| Witassek, F | 1 |
| Burkhardt, B | 1 |
| Eckert, J | 1 |
| Bircher, J | 1 |
| McCracken, RO | 1 |
| Taylor, DD | 1 |
| Terada, M | 1 |
| Kino, H | 1 |
| Akyol, CV | 1 |
| Sano, M | 1 |
| Maurer, K | 1 |
| Decere, M | 1 |
| Fried, B | 1 |
| Chung, MS | 1 |
| Joo, KH | 1 |
| Quan, FS | 1 |
| Kwon, HS | 1 |
| Cho, SW | 1 |
| Zajícek, D | 1 |
| Márová, M | 1 |
| Zahradníková, W | 1 |
| Coperman, DB | 1 |
| Taylor, DH | 1 |
| Morris, DL | 1 |
| Reffin, D | 1 |
| Richards, KS | 1 |
| Rajasekariah, GR | 1 |
| Deb, BN | 1 |
| Dhage, KR | 1 |
| Bose, S | 1 |
| Wangoo, A | 1 |
| Ganguly, NK | 1 |
| Mahajan, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors[NCT02644291] | Phase 1 | 16 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
35 other studies available for mebendazole and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
A Combination of Deworming and Prime-Boost Vaccination Regimen Restores Efficacy of Vaccination Against Influenza in Helminth-Infected Mice.
Topics: Animals; Antinematodal Agents; Coinfection; Disease Models, Animal; Female; Filariasis; Filarioidea; | 2021 |
Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Fibrosis; Hum | 2022 |
Acute Anisakiasis: Pharmacological Evaluation of Various Drugs in an Animal Model.
Topics: Acute Disease; Animals; Anisakiasis; Anthelmintics; Anti-Ulcer Agents; Antinematodal Agents; Disease | 2021 |
Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.
Topics: Animals; Anthelmintics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apopt | 2018 |
Short-course, oral flubendazole does not mediate significant efficacy against Onchocerca adult male worms or Brugia microfilariae in murine infection models.
Topics: Administration, Oral; Animals; Brugia malayi; Disease Models, Animal; Filaricides; Ivermectin; Male; | 2019 |
Efficacy of subcutaneous doses and a new oral amorphous solid dispersion formulation of flubendazole on male jirds (Meriones unguiculatus) infected with the filarial nematode Brugia pahangi.
Topics: Administration, Oral; Animals; Brugia pahangi; Disease Models, Animal; Female; Filariasis; Filaricid | 2019 |
Macrofilaricidal efficacy of single and repeated oral and subcutaneous doses of flubendazole in Litomosoides sigmodontis infected jirds.
Topics: Administration, Oral; Animals; Disease Models, Animal; Embryonic Development; Female; Filariasis; Fi | 2019 |
Development and validation of an Onchocerca ochengi adult male worm gerbil model for macrofilaricidal drug screening.
Topics: Animals; Benzimidazoles; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Filaricides; | 2019 |
Mebendazole reduces vascular smooth muscle cell proliferation and neointimal formation following vascular injury in mice.
Topics: Animals; Apoptosis; Cell Movement; Cell Proliferation; Disease Models, Animal; Hyperplasia; Male; Me | 2014 |
Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose.
Topics: Administration, Oral; Animals; Anthelmintics; Biological Availability; Cellulose; Disease Models, An | 2014 |
Enhancing the bioavailability of mebendazole by integrating the principles solid dispersion and nanocrystal techniques, for safe and effective management of human echinococcosis.
Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Echinococcosis; Female; Humans; Male; | 2016 |
Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model.
Topics: Animals; Brain Neoplasms; Chemistry, Pharmaceutical; Disease Models, Animal; Humans; Mebendazole; Me | 2015 |
Phenolic Metabolites of Dalea ornata Affect Both Survival and Motility of the Human Pathogenic Hookworm Ancylostoma ceylanicum.
Topics: Albendazole; Ancylostoma; Ancylostomatoidea; Ancylostomiasis; Animals; Anthelmintics; Cricetinae; Di | 2016 |
Implication of artemisinin nematocidal activity on experimental trichinellosis: In vitro and in vivo studies.
Topics: Animals; Antinematodal Agents; Artemisinins; Cyclooxygenase 2; Disease Models, Animal; In Vitro Tech | 2017 |
Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice.
Topics: Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Echinococcosis; Echinococcus granulosus; | 2009 |
In vivo evaluation of potential nematicidal properties of ethanol extract of Canthium mannii (Rubiaceae) on Heligmosomoides polygyrus parasite of rodents.
Topics: Animals; Antinematodal Agents; Disease Models, Animal; Ethanol; Feces; Female; Male; Mebendazole; Mi | 2009 |
Chemoprophylactic activity of flubendazole in cystic echinococcosis.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antinematodal Agents; beta-Cyclodextrins; Carboxymethylc | 2010 |
Comparative effect of mebendazole, albendazole, tribendimidine, and praziquantel in treatment of rats infected with Clonorchis sinensis.
Topics: Albendazole; Animals; Antiprotozoal Agents; Clonorchiasis; Clonorchis sinensis; Disease Models, Anim | 2011 |
Effectiveness of various anthelmintics in the treatment of moniliformiasis in experimentally infected Wistar rats.
Topics: Animals; Anthelmintics; Cockroaches; Disease Models, Animal; Female; Helminthiasis; Mebendazole; Mon | 2011 |
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
Topics: Animals; Antinematodal Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell | 2011 |
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
Topics: Animals; Antinematodal Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell | 2011 |
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
Topics: Animals; Antinematodal Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell | 2011 |
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
Topics: Animals; Antinematodal Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell | 2011 |
Nematodicidal activity of flubendazole and its reduced metabolite on a murine model of Trichinella spiralis infection.
Topics: Administration, Oral; Animals; Anthelmintics; Carboxymethylcellulose Sodium; Cyclodextrins; Disease | 2012 |
The Hymenolepis diminuta-golden hamster (Mesocricetus auratus) model for the evaluation of gastrointestinal anticestode activity.
Topics: Administration, Oral; Amidines; Animals; Anticestodal Agents; Cambendazole; Cricetinae; Digestive Sy | 2004 |
[Thoracic hydatid cysts: news].
Topics: Albendazole; Animals; Anthelmintics; Anticestodal Agents; Antinematodal Agents; Benzimidazoles; Dise | 2006 |
Changes in carbohydrate metabolism in golden hamsters infected with Necator americanus.
Topics: Animals; Carbohydrate Metabolism; Cricetinae; Disease Models, Animal; Fatty Acids, Nonesterified; Gl | 1982 |
Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man.
Topics: Adult; Aged; Animals; Benzimidazoles; Circadian Rhythm; Disease Models, Animal; Echinococcosis, Pulm | 1981 |
Mebendazole therapy of parenteral trichinellosis.
Topics: Administration, Oral; Animals; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, D | 1980 |
Effects of mebendazole on Angiostrongylus costaricensis in mice, with special reference to the timing of treatment.
Topics: Angiostrongylus; Animals; Disease Models, Animal; Drug Administration Schedule; Male; Mebendazole; M | 1993 |
Effects of the anthelmintics clorsulon, rafoxanide, mebendazole and arprinocid on Echinostoma caproni in ICR mice.
Topics: Adenine; Animals; Anthelmintics; Dimethyl Sulfoxide; Disease Models, Animal; Dose-Response Relations | 1996 |
Efficacy of flubendazole and albendazole against Trichinella spiralis in mice.
Topics: Albendazole; Animals; Anthelmintics; Disease Models, Animal; Female; Larva; Life Cycle Stages; Meben | 2001 |
[Efficacy of mebendazole in sheep experimentally invaded with larvae of Haemonchus contortus and Trichostrongylus colubriformis in relation to the results of clinical examination].
Topics: Animals; Benzimidazoles; Disease Models, Animal; Haemonchiasis; Mebendazole; Sheep; Sheep Diseases; | 1978 |
An evaluation of the bovine -- Onchocerca gibsoni, Onchocerca gutturosa model as a tertiary screen for drugs against Onchocerca volvulus in man.
Topics: Animals; Cattle; Diethylcarbamazine; Disease Models, Animal; Drug Therapy, Combination; Filaricides; | 1979 |
Comparison of albendazole, mebendazole and praziquantel chemotherapy of Echinococcus multilocularis in a gerbil model.
Topics: Albendazole; Animals; Anthelmintics; Disease Models, Animal; Echinococcosis; Echinococcus; Gerbillin | 1989 |
Response of adult Necator americanus to some known anthelminthics in hamsters.
Topics: Animals; Cricetinae; Disease Models, Animal; Humans; Ivermectin; Mebendazole; Mesocricetus; Necator; | 1989 |
In vivo efficacy of mebendazole in containment of larval cyst mass in early stages of hydatid disease due to Echinococcus granulosus.
Topics: Animals; Disease Models, Animal; Echinococcosis; Echinococcus; Mebendazole; Mice | 1987 |